Format

Send to

Choose Destination
Rheumatology (Oxford). 2020 Feb 1;59(2):442-445. doi: 10.1093/rheumatology/kez284.

IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome.

Author information

1
Division of Rheumatology, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.
2
Pediatric Rheumatology & Immunology, Children's Hospital of Pittsburgh/UPMC, Pittsburgh, PA, USA.
3
Rheumatology, Geneva University Hospitals and University of Geneva, Geneva.
4
AB2Bio, Lausanne, Switzerland.

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center